Related Experiment Video
Updated: Jun 14, 2025
In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease
Insights
Oral semaglutide improved heart function and blood flow in a swine model of coronary artery disease (CAD). This suggests potential benefits for treating ischemic heart conditions, independent of diabetes.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Translational Medicine
Background:
- Coronary artery disease (CAD) is a leading global cause of death.
- Many patients experience residual symptoms and debilitating angina despite current treatments.
- Semaglutide, a GLP-1 agonist, shows promise for cardiovascular risk reduction, but its direct impact on CAD sequelae is understudied.
Purpose of the Study:
- To investigate the effects of oral semaglutide on cardiac function and myocardial perfusion in a large animal model of chronic coronary artery disease.
- To elucidate the underlying mechanisms of semaglutide's action in the context of ischemic heart disease, independent of diabetes or obesity.
Main Methods:
- Induction of coronary artery disease in Yorkshire swine using an ameroid constrictor.
- Administration of oral semaglutide (3 mg) for 5 weeks in treatment animals.
- Assessment of cardiac function using pressure-volume loop catheterization and myocardial perfusion via microsphere injection.
- Mechanistic studies including immunoblotting, immunohistochemistry, and immunofluorescence on ischemic myocardial segments.
Main Results:
- Semaglutide treatment significantly improved left ventricular ejection fraction at rest and during pacing.
- Enhanced myocardial perfusion was observed in the most ischemic regions.
- Reduced perivascular and interstitial fibrosis, along with decreased apoptosis, were noted in semaglutide-treated animals.
- Increased activation of the endothelial-protective AMPK pathway and downstream endothelial nitric oxide synthase were associated with these improvements.
Conclusions:
- Oral semaglutide demonstrated a capacity to augment cardiac function in a large animal model of chronic ischemic heart disease.
- The observed benefits are likely mediated by AMPK-dependent enhancement of endothelial function and improved perfusion to ischemic myocardium.
- This study provides a translational basis for exploring semaglutide as a therapeutic option for patients with chronic ischemic heart conditions.
Objective:
Coronary artery disease (CAD) is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy, and up to 1/3 with debilitating angina amenable neither to procedures, nor to current pharmacologic options. Semaglutide, a glucagon-like peptide 1 agonist originally approved for management of diabetes, has garnered substantial attention for its capacity to attenuate cardiovascular risk. Although subgroup analyses in patients indicate promise, studies explicitly designed to isolate the impact of semaglutide on the sequelae of CAD, independently of comorbid diabetes or obesity, are lacking.
Approach And Results:
Yorkshire swine (n=17) underwent placement of an ameroid constrictor around the left circumflex coronary artery to induce CAD. Oral semaglutide was initiated postoperatively at 1.5 mg and scaled up in 2 weeks to 3 mg in treatment animals (SEM, n=8) for a total of 5 weeks, while control animals (CON, n=9) received no drug. All then underwent myocardial harvest with acquisition of perfusion and functional data using microsphere injection and pressure-volume loop catheterization. Immunoblotting, immunohistochemistry, and immunofluorescence were performed on the most ischemic myocardial segments for mechanistic elucidation. SEM animals exhibited improved left ventricular ejection fraction, both at rest and during rapid myocardial pacing (both p<0.03), accompanied by increased perfusion to the most ischemic myocardial region at rest and during rapid pacing (both p<0.03); reduced perivascular and interstitial fibrosis (both p <0.03); and apoptosis (p=0.008). These changes were associated with increased activation of the endothelial-protective AMPK pathway (p=0.005), coupled with downstream increases in endothelial nitric oxide synthase (p=0.014).
Conclusion:
This study is the first to reveal the capacity of oral semaglutide to augment cardiac function in the chronically ischemic heart in a highly translational large animal model, likely through AMPK-mediated improvement in endothelial function and perfusion to the ischemic myocardium.
